Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gynecologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma of Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Angiogenesis Inhibitors × Thoracic × Clear all
NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Tang-Du Hospital

Phase 2 Not yet recruiting
178 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Hunan Cancer Hospital

Phase 2 Unknown
63 enrolled
Thoracic

Adenocarcinoma of Lung

NCT05507606 2022-08-19

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03461185 2018-03-09

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

Xinqiao Hospital of Chongqing

Phase 2 Unknown
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡